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Diffuse large B cell lymphoma
PET
a b s t r a c t
INTRODUCTION: Extranodal lymphoma (ENL) in the muscles is a rare manifestation of non-Hodgkin
lymphoma (NHL). The aim of this case report is to describe and evaluate the clinical presentation and
important radiologic features of ENL affecting the musculoskeletal system.
PRESENTATION OF CASE: We present a 52-year-old female with a 3-week history of left gluteal pain.
Computed tomography (CT) showed a non-uniformly early enhancing mass in the left gluteal muscle,
the tumor demonstrating central necrosis and adjacent bone involvement. Fluorine-18 ﬂuorodeoxyglu-
cose positron emission tomography (18F-FDG PET)/CT showed areas of increased 18F-FDG uptake in
the left gluteal musculature, pelvic bones, para-aortic and mediastinal lymph nodes and both lungs.
Histopathological examination showed a diffuse large B cell lymphoma (DLBCL). After 8 cycles of R-CHOP
chemotherapy, the mass in the left gluteal muscle has completely disappeared
DISCUSSION: Although destructive tumor originating in the gluteal muscle with adjacent bone involve-
ment is more common in soft tissue sarcoma, lymphoma should be regularly included in the differential
diagnosis. While CT is a useful modality for assessing soft tissue masses, disruption and injury of the
surrounding tissues, PET/CT fusion is superior for the detection of unexpected extranodal sites of disease,
or for exclusion of disease in the presence of nonspeciﬁc extranodal CT ﬁndings.
CONCLUSION: A rapid growth pattern and destructive masses that invade adjacent structures on CT are
key ﬁndings of DLBCL, and 18F-FDG PET/CT is a useful imaging modality to accurately determine the
disease stage and disease aggressiveness of NHL.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Malignant lymphomas are a heterogeneous group of malignan-
cies of the B cells or T cells that usually originate in the lymph
nodes, although they can originate in any part of the body [1–3].
However, extranodal lymphoma (ENL) in themuscles as an isolated
manifestation is very rare, accounting for 1.5–8.3% of non-Hodgkin
lymphoma (NHL) cases [4–6]. Clinically, the presence of corti-
cal bone destruction in association with large soft-tissue masses
arising in the skeletal muscle, favors the diagnosis of soft tis-
sue sarcoma, malignant musculoskeletal tumor such as malignant
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ﬁbrous histiocytoma (MFH),malignant neurogenic tumor (MPNST)
or metastasis rather than malignant lymphoma [3,4,7,8].
Despite advances in imaging devices over the past decade,
accurate diagnosis of soft tissue tumors remains a challenge for
clinicians, requiring a close team approach between the surgical
oncologist, musculoskeletal radiologist and pathologist. Here we
present a rare case of extranodal lymphoma originating in the
gluteal muscle, with aggressive bone erosion, indicative of primary
bone involvement. We believe that our case adds an important
piece of evidence to the clinically relevant problem of appropri-
ate diagnostic strategy for an unusual presentation of malignant
lymphoma.
2. Case report
A 52-year-old female with a 3-week history of progressive left
glutealpainwas referred toouroutpatient surgicaldepartment. She
waspreviouslyhealthybuthadahistoryof night sweats andweight
loss over the prior 2 months. Upon physical examination, a large
ﬁrm mass was observed in the left buttock, with no inﬂammation
http://dx.doi.org/10.1016/j.ijscr.2015.01.024
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Contrast-enhanced computed tomography (CT) of the pelvis demonstrating
the left glutealmass (arrow). (A) CT showedanon-uniformly enhancinghypervascu-
larmasswith central necrosis in the left glutealmuscle. (B) The tumor demonstrated
adjacent bone involvement with destruction of the sacroiliac joint.
of the skin. No peripheral lymphadenopathy was detected despite
thorough examination of the whole body. Standard biochemistry
and hematology studies revealed normal results, except for mild
elevation of serum lactic dehydrogenase (LDH) and C-reactive pro-
tein (CRP). Contrast-enhanced computed tomography (CT) scan of
the pelvis revealed a non-uniformly early enhancingmass, approx-
imately 51×64mm in size, in the left gluteal muscle (Fig. 1A). The
tumor demonstrated central necrosis and adjacent bone involve-
ment, with destruction of the sacroiliac joint (Fig. 1B). CT scan of
the chest showed patchy consolidation in the lower lobes of both
lungs. Fluorine-18 ﬂuorodeoxyglucose positron emission tomog-
raphy (18F-FDG PET)/CT demonstrated a large area of increased
18F-FDGuptake in the left glutealmusculature [maximumstandard
uptake value (SUVmax) = 34], the posterior aspect of the left ileum
and the sacrum (Fig. 2A). Whole-body 18F-FDG PET/CT identiﬁed
intense 18F-FDG uptake by the para-aortic and mediastinal lymph
nodes, and faint scattered 18F-FDG uptake by both lungs (Fig. 2B).
Based on these ﬁndings, the clinical and radiographic differen-
tial diagnosis was soft tissue sarcoma, malignant lymphoma or
metastasis derived from small cell carcinoma of the lung. We then
proceeded with an open biopsy of the left gluteal mass for further
diagnosis and treatment planning. Pathological studies of the spec-
imen demonstrated dense and diffuse inﬁltration and proliferation
of large atypical lymphoid cells, accompanied by small lympho-
cytes (Fig. 3A). Immunohistochemical studies showed that the large
atypical lymphoid cells were positive for LCA, CD20 and bcl-6, and
werenegative for cytokeratin, S-100, alpha-SMAandbcl-2 (Fig. 3B).
Further, approximately 45% of the large atypical lymphoid cells
were positive for MIB-1(Ki-67). Thus, from these results, we diag-
nosed diffuse large B cell lymphoma (DLBCL) of the left buttock.
After staging work-up, including bone marrow biopsy, the patient
was ﬁnally diagnosed with stage IV DLBCL, low-intermediate
risk of the international prognostic index (IPI). Immediately after
Fig. 2. Fluorine-18 ﬂuorodeoxyglucose positron emission tomography (18F-FDG
PET)/CT images. (A) Axial 18F-FDG PET/CT view demonstrated large areas of
increased 18F-FDG uptake in the left gluteal musculature [maximum standard
uptake value (SUVmax) = 34], the posterior aspect of the left ileum (arrow) and
the sacrum. (B) Whole-body 18F-FDG PET/CT identiﬁed strong 18F-FDG uptake by
the para-aortic and mediastinal lymph nodes (arrow), and faint scattered 18F-FDG
uptake by both lungs (SUVmax =3.8).
diagnosis, the patient has received 8 cycles of R-CHOP chemother-
apy, and as a result the mass in the left gluteal muscle has
completely disappeared (Fig. 4A, B). The patient achieved complete
remission after chemotherapy and is currently under the regular
follow-up evaluation.
3. Discussion
Malignant lymphomas in the musculoskeletal organs are pre-
dominantly a manifestation of disseminated lymphoma [3,4].
Common sites for the development of ENL are the skin, head, neck
and gastrointestinal tract; primary lymphoma of the skeletal mus-
cle is extremely rare [1–4]. To date, only a few cases of malignant
lymphoma originating in the gluteal muscle have been reported
in the English literature [5,7,9,10]. Textbooks present the common
aspects of ENL in detail, but the published literature on the unex-
pected manifestations of NHL, such as soft tissue masses invading
adjacent structures, is inadequate. These tumors can have an atyp-
ical presentation, which can lead to diagnostic difﬁculty.
The most meaningful radiologic features of ENL affecting the
musculoskeletal system are permeative lytic destruction, although
mixed lytic and blastic (sclerotic) lesions have been reported
[3,11,12]. Patients with primitive or poorly differentiated tumors
were more likely to have bone involvement than patients with
well differentiated lymphomas [12]. Although the compartmental
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Fig. 3. Histological and immunohistochemical examination of the resected speci-
men of the left buttock. (A) Hematoxylin and eosin (H–E) staining revealed diffuse
inﬁltration with large atypical lymphoid cells with prominent nucleoli (×400). (B)
CD20 immunohistochemical staining demonstrated the presence of large atypical
lymphoid cells on the membrane (×400).
location of a lesion usually provides a differential diagnosis, the
intrinsic imaging characteristics, including signal intensity, often
addspeciﬁcity.WhileCT is ausefulmodality for assessing soft tissue
masses, disruption and injury of the surrounding tissues, periosteal
reaction and sequestration [2,3,11–13], it has some limitations
in terms of staging of the disease, because of its low sensitivity
in detecting lymphomatous involvement of normal-sized lymph
nodes, bone marrow and spleen [13,14]. A recently published sys-
tematic reviewarticle showed that PET/CT fusion is superior toboth
CT alone and PET alone in the initial staging and restaging after
treatment [15]. Regarding extranodal involvement, the sensitivity
and speciﬁcity were 88% and 100% for PET/CT and 50% and 90% for
contrast enhanced CT, respectively [14]. A previous study in NHL
patients reported that the disease was up-staged by PET/CT in 31%
(mostly in stages I and II) and down-staged in only 1% of patients
compared with CT alone. As a result, the treatment strategy was
modiﬁed in 25% of patients according to CT versus PET/CT ﬁnd-
ings [16]. Although its diagnostic efﬁcacy for indolent lymphoma
remains unclear, PET/CT can serve as a standard imaging modality
for the detection of unexpected extranodal sites of disease, or for
exclusion of disease in the presence of nonspeciﬁc extranodal CT
ﬁndings [2–4,11,13].
In addition to imaging studies, a deﬁnitive diagnosis of lym-
phoma requires histological examination of the specimen. For
ENL patients, DLBCL is among the most common histological
types, with expression of pan-B-cell markers, such as CD20
[1,17,18]. DLBCL often shows a rapid growth pattern and typically
presents as large destructive masses that may inﬁltrate and invade
Fig. 4. Contrast-enhanced CT of the pelvis after chemotherapy. (A) CT showed the
mass in the left gluteal muscle has completely disappeared (arrow). (B) CT showed
the erosion of the sacroiliac joint still remained (arrow), showing the destructive
characteristics of the tumor.
adjacent structures [1,17,18]. In a recent report which analyzed
NHL patients, the relationship between SUVmax on 18F-FDG PET
anddisease aggressivenesswas evaluated [19,20]. Forpatientswith
DLBCL, the 3-year progression-free survival rates for patients with
low and high SUVmax were 90% and 39%, respectively, indicat-
ing that low SUVmax is a good independent prognostic factor [20].
Therefore, 18F-FDG PET is a useful imaging modality to study the
hallmarks of progression of the disease and its response to treat-
ment [19,20].
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